Skip to main content
Cantargia logo

Cantargia — Investor Relations & Filings

Ticker · CANTA ISIN · SE0023312970 LEI · 549300GKWRT7RXI4VS85 ST Manufacturing
Open in API
Filings indexed 511 across all filing types
Latest filing 2024-11-29 Regulatory Filings
Country SE Sweden
Listing ST CANTA

About Cantargia

https://cantargia.com/en/

Cantargia is a biotechnology company that develops antibody-based therapies targeting the interleukin-1 receptor accessory protein (IL1RAP). This protein is involved in signaling pathways that can drive cancer and inflammatory diseases. The company's lead asset, nadunolimab (CAN04), is a clinical-stage antibody under investigation for the treatment of various forms of cancer, including pancreatic cancer. Cantargia also developed the CAN10 program, an antibody targeting IL1RAP for autoimmune and inflammatory conditions, which was acquired by Otsuka Pharmaceutical.

Recent filings

Filing Released Lang Actions
Cantargia utökar CAN10:s fas I kliniska program baserat på positiva resultat
Regulatory Filings Classification · 95% confidence The document is a press release from Cantargia AB announcing an expansion of their Phase I clinical trial for CAN10 based on positive preliminary results (safety, biomarkers, pharmacokinetics). It details the scientific rationale, the change in protocol (adding more cohorts), and future plans (Phase II start in H2 2025). The text concludes with boilerplate information about the company and a link to a PDF attachment titled similarly to the press release itself. Crucially, the document ends with a statement indicating it is information the company is obligated to disclose under the EU Market Abuse Regulation and lists the contact person for publication. This structure strongly suggests a regulatory announcement or press release detailing operational/clinical progress, rather than a formal financial report (like 10-K or IR) or a transcript. Since it is a specific operational update/announcement that doesn't fit the other specific categories (like DIV, CAP, MANG), it falls best under the general 'Regulatory Filings' (RNS) category, which serves as a broad category for official company announcements not covered elsewhere, especially those mandated by market regulations.
2024-11-29 Swedish
Interim / Quarterly Report 2024
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Delårsrapport' (Interim Report) for the period 'Januari – september 2024'. It contains comprehensive financial data, including income statements, balance sheets, cash flow analysis, and management commentary on business trends and clinical trial progress. It is a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. 9M 2024
2024-11-15 Swedish
Interim / Quarterly Report 2024
Interim / Quarterly Report Classification · 100% confidence The document is explicitly titled 'Interim Report' and covers the period from January to September 2024. It contains comprehensive financial information, including a Statement of Comprehensive Income, Statement of Financial Position, Statement of Cash Flow, and an Auditor's Report. It is not a short announcement or a certification, but the full interim financial report itself, fitting the definition of an Interim/Quarterly Report (IR). 9M 2024
2024-11-15 English
Cantargia presenterar valberedning inför årsstämman 2025
AGM Information Classification · 95% confidence The document is a press release from Cantargia AB announcing the appointment of a nomination committee (valberedning) in preparation for the 2025 Annual General Meeting. It details the committee members, their shareholding representation, and the process for shareholders to submit proposals. This type of announcement regarding board/governance preparation for an upcoming AGM falls under the category of Governance Information (CGR) as it pertains to the internal rules and board structure preparation.
2024-11-13 Swedish
Cantargia presents Nomination Committee ahead of 2025 AGM
Board/Management Information Classification · 100% confidence The document is a press release announcing the appointment of a Nomination Committee ahead of the 2025 Annual General Meeting. It provides details on the committee members, their tasks, and how shareholders can submit proposals. It does not contain the actual AGM materials or voting results, but rather serves as a corporate announcement regarding the preparation for the meeting. Given the nature of the announcement and the 'Menu vs Meal' rule, this is a regulatory announcement regarding corporate governance preparations.
2024-11-13 English
Major Shareholding Notification 2024
Major Shareholding Notification Classification · 99% confidence The document details a change in shareholding, specifically reporting that Avanza Bank Holding AB, through its subsidiary, now holds 5.00018% of the shares in CANTARGIA AB. The table explicitly states the 'Reason for major shareholding notification' as 'Buy' and lists the resulting distribution of total holdings, including the number of shares and the percentage of voting rights. This structure perfectly matches the definition of a Major Shareholding Notification, which corresponds to the filing code MRQ.
2024-11-07 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.